Occurrence of a novel cleavage site for cathepsin G adjacent to the polybasic sequence within the proteolytically sensitive activation loop of the SARS-CoV-2 Omicron variant: The amino acid substitution N679K and P681H of the spike protein

Zhadyra Mustafa, Hubert Kalbacher, Timo Burster

Abstract

The serine proteases neutrophil elastase (NE), proteinase 3 (PR3), cathepsin G (CatG), and neutrophil serine protease 4 (NSP4) are secreted by activated neutrophils as a part of the innate immune response against invading pathogens. However, these serine proteases might be adopted by viruses to mediate viral surface protein priming resulting in host cell entrance and productive infection. Indeed, NE and PR3 hydrolyze the scissile peptide bond within the proteolytically sensitive polybasic sequence of the activation loop of SARS-CoV-2 located at the S1/S2 interface of the Spike (S) protein; an amino acid motif which differs from SARS-CoV-1. The occurrence of novel SARS-CoV-2 variants and substitution of distinct amino acids at the polybasic sequence prompts serious concerns regarding increased transmissibility. We propose that a novel cleavage site by CatG of the Omicron variant and the increased substrate turnover of the Delta variant by furin within the polybasic sequence should be considered for increased transmission of SARS-CoV-2 variants.

Introduction

The severe acute respiratory syndrome coronavirus 2 Wuhan, WIV04 (SARS-CoV-2 Wuhan) and their variants, the causative agent of coronavirus disease 2019 (COVID-19), continuously mutates, leading to a possible increased transmission of the virus [1, 2]. The attachment of SARS-CoV-2 to the host cell is central in viral infectivity, thereby the Spike (S) protein represents a crucial determinant for binding to the receptor human angiotensin-converting enzyme 2 (hACE2) [3]. During viral replication the S1/S2 interface of the S protein is partly cleaved (primed) largely by furin in the infected producer cell, and the released virion is further activated by hydrolysis of S2’ subunit mainly by cell surface transmembrane protease serine
subtype 2 (TMPRSS2) in order to generate the fusion peptide, which facilitates membrane fusion and lastly entrance of SARS-CoV-2 [4, 5]. Protease-mediated entry characterizes one of the main factors of successful productive infection of SARS-associated coronaviruses [6]. As a result, acquisition of novel occurring amino acid substitutions within the S protein might provoke an increased priming of SARS-CoV-2 and supports viral transmission. The prevalence of new SARS-CoV-2 variants compared to SARS-CoV-2 (Wuhan) might be explained by an increased proteolytic priming of the S protein at the polybasic region (preprint, https://doi.org/10.1101/2021.08.12.456173); amino acid substitutions at this site can be considered as an additional immune evasion strategy by SARS-CoV-2. A SARS-CoV-2 variant, referred to as SARS-CoV-2 (Alpha, B.1.1.7), comprises three deletions and seven substitutions in the S protein compared to the SARS-CoV-2 (Wuhan) [7]. SARS-CoV-2 (Kappa, B.1.617.1) as well as SARS-CoV-2 (Delta, B.1.617.2) harbor three key mutations in the S protein [8] and show a notable increase in transmissibility [9]. For instance, the Alpha variant augments transmissibility to 40–70% compared to the ancestral SARS-CoV-2 (Wuhan) virus, whereas the Delta variant appears to be 60% more transmissible than the Alpha variant [10]. Both Alpha and Delta variants have a mutation in the polybasic sequence, precisely at P681H and P681R, respectively [11] compared to the B.1.1.529 lineage SARS-CoV-2 (Omicron) which has two amino acid substitutions at the polybasic sequence: N679K and P681H. These substitutions have also been described for C.1.2 (N679K) and in 11% of cases of C.1.2 (N679K and P681H) (doi.org/10.1101/2021.08.20.21262342).

The fact that lymphocytopenia is observed with an increased prevalence in patients with a severe course of COVID-19 suggests that those inflammatory conditions, associated with mortality and morbidity, are caused by leukocytes rather than lymphocytes [12]. An increase in neutrophil counts and an elevated neutrophil-to-lymphocyte ratio (NLR) were postulated to be predictive for the prognosis of severe cases of COVID-19 [13]. Neutrophils, which infiltrate the site of infection creating innate immunity, are activated to release neutrophil serine proteases (NSPs). Of these, neutrophil elastase (NE), proteinase 3 (PR3), cathepsin G (CatG), and neutrophil serine protease 4 (NSP4) are resident in granules, and are recruited to the cell surface to be secreted into the extracellular space, which mediate host defense against various pathogens [14, 15]. Crucially, proteomic analysis of nasopharyngeal swabs of patients with SARS-CoV-2 revealed an increased amount of NE and CatG compared to non-infected individuals [16]. Additionally, neutrophil-derived NE and PR3 cleave the SARS-CoV-2 S protein adjacent to the polybasic insert, an amino acid motif encompassing RRAR, which suggests a role of S protein priming by NE and PR3 [17]. Thus, the frequency of NSPs in the nasal mucosa might contribute to S protein cleavage.

Here, we focused on the polybasic sequence of the proteolytically sensitive activation loop and examined whether the proteolytic cleavage by NSPs and furin is dependent on amino acid substitution found in different SARS-CoV-2 variants.

**Material and methods**

**In silico analysis of peptides**

FASTA format sequences of the S protein peptides spanning the S1/S2 interface of SARS-CoV-1 (UniProtKB: P0DTC2) 660YHTVSLRSTSQKS673, SARS-CoV-2 (Wuhan, WIV04, UniProtKB: P59594) 678TNSPRRARSVASQS691, SARS-CoV-2 P681H (Alpha) 678TNSHR RARSVASQS691, SARS-CoV-2 P681R (Delta) 678TNSRRRARSVASQS691, SARS-CoV-2 (C.1.2) 674YQTQTKSRRARSVASQS691, and SARS-CoV-2 (Omicron) 674YQTQTKSHRRARSVASQS691 were retrieved from UniProtKB (https://www.uniprot.org). The peptide sequences were assessed for potential cleavage sites using *in silico* analysis. The peptides were
evaluated using the program ExPASy Peptide Cutter (https://web.expasy.org/peptide_cutter/) against human NE (EC 3.4.21.37). This software predicts the possible cleavage sites of the given peptide sequence by distinct proteases.

Analysis of peptide digestion in vitro

SARS-CoV-1 \textit{660}YHTVSLLRSTSQKS\textit{673}, SARS-CoV-2 (Wuhan) \textit{678}TNSPRRARVSQS\textit{691}, SARS-CoV-2 P681H (Alpha) \textit{678}TNNSHRARVSQS\textit{691}, SARS-CoV-2 P681R (Delta) \textit{674}TNSRRARVSQS\textit{691}, SARS-CoV-2 (Wuhan) \textit{674}YQTQTNSPRRARVSQS\textit{691}, SARS-CoV-2 (Alpha) \textit{674}YQTQTNSHRRARVSQS\textit{691}, SARS-CoV-2 (C.1.2) \textit{672}YQTQTKSPRRARVSQS\textit{691}, or SARS-CoV-2 (Omicron) \textit{674}YQTQT\textit{KSHRRARVSQS}\textit{691} peptides, spanning the polybasic sequence, were synthesized by EMC Microcollections GmbH (Tübingen, Germany) and purified by reversed-phase HPLC using a C18 250 x 8 column (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). The precise mass was determined by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (Reflex IV, Bruker Daltonics, Bremen, Germany) with 2,5-Dihydroxybenzoic acid (DHB) matrix (Reflex IV, Bruker Daltonics). The indicated peptides were lyophilized and dissolved in PBS pH 7.4 (10 mg/ml).

200 μg/ml SARS-CoV peptides were incubated with human NE (4 μg/ml, Cat. No.: SE563, elastase from leukocytes of human sputum, Elastin Products Company Inc., EPC, Owensville, MO, USA or neutrophil-derived human NE, PN: 16-14-051200, Lot No. EH 2020–03, Athens Research and Technology, Athens, GA, USA), human CatG (4 μg/ml, Cat. No.: E-002, neutrophil-derived human CatG, BioCentrum Ltd., Krakow, Poland or neutrophil-derived CatG, PN: 16-14-030107, Lot No. CG 2017–01, Athens Research and Technology, Athens, GA, USA), CatG inhibitor (10 μM of Suc-Val-Pro-Phe\textsubscript{2}(OPh)\textsubscript{2} (SucVPF) \cite{18}, 4 μg/ml (4 μl recombinant furin harboring 5 mM CaCl\textsubscript{2} was added to 94 μl PBS pH 7.4 with 2 μl peptide) recombinant human furin (Cat. No. 450–47, Lot No. 1011516, Peprotech, Cranbury, NJ, USA), or 4 μg/ml PR3 (Athens Research and Technology, Athens, GA, USA) in PBS pH 7.4 for 2 h at 37˚C. The resulting fragments from the digest were resolved by using an Intelligent Pump L-6200 (Merck-Hitachi, Darmstadt, Germany) connected to a Reprosil 100, 250 x 2 mm, C18 with 5 μm particle diameter column (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). The separation of the fragments from the peptide cleavage was performed by using a linear acetonitrile gradient and peptides were detected at 214 nm by UV vis detector L-4200 (Merck-Hitachi, Darmstadt, Germany) as well as a Chromato-Integrator D-2500 (Merck-Hitachi, Darmstadt, Germany).

The samples were analyzed by mass spectrometry (MALDI-TOF, Reflex IV, Bruker Daltonics, Bremen, Germany) and manually linked to predicted peptides created by an ExPASy FindPept tool (https://web.expasy.org/findpept/, Swiss Institute of Bioinformatics, Lausanne, Switzerland).

Statistical analysis

One-way ANOVA for multiple comparison was used. Tukey HSD test for statistical significance was expressed as P-value < 0.05 equals * and P-value < 0.01 equals ** and is drawn in the diagram (VassarStats: Website for Statistical Computation, http://vassarstats.net).

Results

Protease-mediated SARS-CoV-2 entrance of the host cell is one of the major factors of a successful infection. The appearance of novel amino acid substitutions within the S protein might enhance viral transmission, escape natural- as well as vaccine-mediated immunity, and
increase pathogenicity [19, 20]. Histamine or arginine substitutions might generate further cleavage sites within the proteolytically sensitive activation loop (Fig 1).

In a first set of investigations, a prediction approach of cleavage sites for the SARS-CoV-1 660 YHTVSLLRSTSQKS 673, SARS-CoV-2 (Wuhan) 678 TNSPRRARVVASQS, SARS-CoV-2 P681H (Alpha) 684 THRARRVASQS, SARS-CoV-2 P681R (Delta) 688 RRARRVASQS, SARS-CoV-2 N679K (C.1.2) 691 TKSPRRARVVASQS, and SARS-CoV-2 P681N679K P681R (Omicron) 696 TKSHRRARVVASQS, peptides, spanning the polybasic sequence of the S1/S2 interface, were performed for NE by using ExPASy (https://web.expasy.org/peptide_cutter/). Based on these outcomes, NE processed the SARS-CoV-1 peptide at 663 VS and the variants of SARS-CoV-2 peptides between 684 AR, 688 VA, and 688 AS (Fig 2). Of note, only NE for substrate cleavage prediction was available in ExPASy for NSPs.

In order to verify these results experimentally, SARS-CoV-1, SARS-CoV-2 (Wuhan), SARS-CoV-2 P681H (Alpha), and SARS-CoV-2 P681R (Delta), SARS-CoV-2 N679K (C.1.2), and SARS-CoV-2 N679K P681R (Omicron) peptides were synthesized and incubated with the indicated proteases (Fig 3). The resulting fragments were resolved as well as quantified by HPLC (Fig 3A) and analyzed by using mass spectrometry (Fig 3B). CatG digested SARS-CoV-1 peptide, in contrast to the different SARS-CoV-2 peptides (Wuhan, Alpha, Delta, C.1.2) which failed to be hydrolyzed by CatG (Fig 3A, upper panel). However, CatG cleaved SARS-CoV-2 N679K P681R (Omicron) peptide with a substrate turnover rate of approximately 20%. The substrate turnover of SARS-CoV-2 (Wuhan), SARS-CoV-2 P681H (Alpha), and SARS-CoV-2 P681R (Delta) by furin was increased when compared to SARS-CoV-1; however, the turnover rate was only significant for SARS-CoV-2 P681R (Delta) and SARS-CoV-2 P681R (C.1.2) as compared to SARS-CoV-2 (Fig 3A, lower panel).

Next we sought to determine the precise position where these peptides were hydrolyzed. CatG cleaved the SARS-CoV-1 peptide bond between 666LR667 [17] (Fig 3B, left panel; S1 Fig). Strikingly, a novel cleavage site was detected for SARS-CoV-2 N679K P681R (Omicron) peptide between 679KS686. The serine protease furin did not digest SARS-CoV-1, in contrast to SARS-CoV-2 peptides which were hydrolyzed between 685RS686 (Fig 3B, middle panel; S1 Fig).
NE digested SARS-CoV-1 between 663 VS 664 and were less prominent between 669 TS 670 (Fig 3B, right panel; S1–S3 Figs). NE catalyzed the hydrolysis of all SARS-CoV-2 variants at 687 VA 688 and 688 AS 689. PR3 cleaved the peptides between 687 VA 688 and 688 AS 689. In an additional experiment, we tested whether the digestion pattern might change when SARS-CoV-2 N679K P681R (Omicron) peptide will be incubated with CatG and NE or CatG.

https://doi.org/10.1371/journal.pone.0264723.g002

Fig 2. NE cleavage site prediction covering the polybasic sequence of the activation loop of the S protein. Potential cleavage sites of NE at the proteolytically sensitive activation loop of SARS-CoV-1, SARS-CoV-2 (Wuhan), SARS-CoV-2 P681H (Alpha), SARS-CoV-2 P681R (Delta), SARS-CoV-2 N679K (C.1.2), and SARS-CoV-2 N679K P681R (Omicron) peptides were mapped using “ExPASy peptide cutter”. Red arrows indicate cleavage sites.
Fig 3. Proteolytic cleavage sites within the polybasic sequence of the proteolytically sensitive activation loop. A) The peptides (200 μg/ml) were incubated with 4 μg/ml of the respective protease for 2h at 37˚C and followed by quantification of the peptide turnover by using HPLC. Of note, quantification of substrate (SARS-CoV-2 variants) turnover by NE was not completely feasible due to the fact that the undigested peptide and the digestion pattern migrated on the same HPLC peak. The summary of substrate turnover by CatG (SARS-CoV-2 Omicron, n = 5) or furin (n = 3) is shown in a bar diagram. P < 0.05 (*) or P < 0.01 (**). CatG inhibitor = CatGinh.

B) Catalytic cleavage sites of CatG, furin, and NE are summarized. Red arrows indicate cleavage sites and blue bars the digestion pattern (peptides) detected by mass spectrometry. Of note, green bars represent less prominent peptides. CatG, furin, and NE at least n = 2 independent experiments.

https://doi.org/10.1371/journal.pone.0264723.g003
furin, and NE. Indeed, furin largely directed the processing of the peptide in contrast to NE, since NE generated fragments were not detected (Fig 4).

Discussion

According to the ExPASy data, NE cleaves the polybasic sequence of the proteolytically sensitive activation loop of SARS-CoV-2 Wuhan, Alpha, and Delta variants at three different positions (Fig 2). NE hydrolyzed the SARS-CoV-1 peptide after threonine (T679) since NE has considerable preference for this amino acid at P1 [21]. This is a limitation of the prediction tool since only the P1 position of the peptide and a preference for valine and alanine is considered for NE, underlying the importance for an experimental verification of the obtained data.

The amino acid substitution increased the digestion capacity of furin (Wuhan → Alpha → Delta, Fig 3A) within the polybasic sequence which might be one reason for increased transmission. Whether the novel cleavage site performed by CatG for SARS-CoV-2 Omicron peptide, carrying the mutations N679K and P681H, might increase infectivity and transmissibility need to be investigated by a cell-based assay. An additional limitation of our investigation is the fact that the complete S protein instead of peptides should be used in antigen processing. Furthermore, the increased turnover capacity of furin and the fact that furin (CatG) controlled the processing of SARS-CoV-2 N679K P681R (Omicron) peptide in contrast to NE, indicate to target furin and, most likely, CatG with selective protease inhibitors as a logical consequence to interfere with the priming of the S protein.

One report suggested that TMPRSS2 is the protease responsible for the cleavage of the polybasic insert of SARS-CoV-2 [22]. Other studies have considered that furin digests at this site and TMPRSS2 at the S2' position [4, 20]. However, knockout of furin in target cells did not substantially affect the cleavage of the S1/S2 interface, and loss of furin function reduced but not completely prevented SARS-CoV-2 infection of host cells, indicating that other cellular
proteases additionally prime the S protein [23]; possibly NE and in the case of SARS-CoV-2 Omicron CatG.

Substrate recognition and specificity by proteases can be altered by glycans [24]. It has been suggested that proline at the position 681 in SARS-CoV-2 allows an addition of O-linked glycans to nearby residues, leading to the creation of a mucin-like domain that shields antigen processing [25], which is circumvented by the introduction of an arginine residue in SARS-CoV-2 P681R. Our data did not indicate an increased cleavage of the polybasic sequence of the Alpha variant by furin (Fig 3B) or NE (S3 Fig), the enhanced transmissibility might be rather true by elevated receptor-binding to the S protein [26], even though these findings are controversial [27], or additional proteases might be responsible for higher transmissibility of SARS-CoV-2 (Alpha). Strikingly, the P681R substitution is crucial for viral replication which has been suggested by reverting the P681R substitution to a wild-type P681 of the SARS-CoV-2 (Delta) background. Moreover, the higher replication of the Delta variant cannot be explained by the possibly enhanced S protein/ACE2 receptor binding since RBD of the Alpha variant has a higher affinity to ACE2 in contrast to the RBD of the Delta variant. The author hypothesized that furin might be responsible for increased transfection by enhanced priming of the S protein at the P681R substitution (preprint, https://doi.org/10.1101/2021.08.12.456173), which could be explained by our findings of increased SARS-CoV-2 P681R (Delta) substrate turnover by furin. Of note, the hydrolysis of the S1/S2 interface by furin, located in the trans-Golgi network, provokes a partial release of the S1 subunit of the S protein trimer [28].

Conclusions

Previously, a study demonstrated that the infection rate of SARS-CoV-1 was increased by porcine pancreas-derived elastase [6], NE and CatG levels were increased in nasopharyngeal swabs of SARS-CoV-2 patients in comparison to the control group [16], and our in vitro data using NSPs and furin support the concept that proteolytic digestion of the S protein adjacent to the polybasic sequence play a role in priming of the S protein in an early event and might be one of several reasons for increased transmission of novel variants. Hypothetically, such priming by neutrophil-derived serine proteases and novel occurring amino acid substitution in the SARS-CoV-2 S protein can be understood as an immune evasion strategy by the virus.

Supporting information

**S1 Fig. Mass spectrometry data.** Summary of the mass spectrometry data (the masses of undigested peptides were not included). The digestion pattern was analyzed by HPLC and mass spectrometry.

(PPTX)

**S2 Fig. Processing of SARS-CoV-1 peptide by NE and PR3.** The SARS-CoV-1 peptide was incubated with NE or PR3 and the digestion pattern was quantified by HPLC.

(PPTX)

**S3 Fig. Processing of SARS-CoV-2 Wuhan and SARS-CoV-2 Alpha peptides by NE.** SARS-CoV-2 Wuhan and SARS-CoV-2 Alpha peptides were incubated with NE and the digestion pattern was quantified by HPLC.

(PPTX)

**S4 Fig. Processing of SARS-CoV-2 (Wuhan), SARS-CoV-2 P681H (Alpha), SARS-CoV-2 N679K (C.1.2), and SARS-CoV-2 N679K P681R (Omicron) peptides by PR3.** Peptides were incubated with PR3 and the digestion pattern was analyzed by HPLC and mass spectrometry,
(n = 2).

S5 Fig. Summary of statistical analysis. One-way ANOVA was used for the statistical analysis of the data found in Fig 3.

Acknowledgments
We appreciate the support of Reinhold Schirmbeck (University Hospital Ulm, Internal Medicine I, Ulm, Germany) regarding TMPRSS2 and Jozef Oleksyszyn for Suc-Val-Pro-Phe\textsubscript{OPh} (Wroclaw University of Science and Technology, Faculty of Chemistry, Wroclaw, Poland).

Author Contributions
Formal analysis: Hubert Kalbacher, Timo Burster.
Funding acquisition: Timo Burster.
Investigation: Hubert Kalbacher, Timo Burster.
Methodology: Hubert Kalbacher, Timo Burster.
Project administration: Timo Burster.
Software: Zhadyra Mustafa, Hubert Kalbacher.
Supervision: Timo Burster.
Validation: Hubert Kalbacher.
Visualization: Zhadyra Mustafa.
Writing – original draft: Zhadyra Mustafa.
Writing – review & editing: Timo Burster.

References
1. Mishra SK, Tripathi T. One year update on the COVID-19 pandemic: Where are we now? Acta Trop. 2021; 214:105778. Epub 2020/12/01. https://doi.org/10.1016/j.actatropica.2020.105778 PMID: 33253656; PubMed Central PMCID: PMC7695590.
2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270–3. Epub 2020/02/06. https://doi.org/10.1038/s41586-020-2012-7 PMID: 32015507; PubMed Central PMCID: PMC7095418.
3. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020; 181(2):281–92 e6. Epub 2020/03/11. https://doi.org/10.1016/j.cell.2020.02.058 PMID: 32155444; PubMed Central PMCID: PMC7102599.
4. Bestle D, Heindl MR, Limburg H, Van Lam van T, Pilgram O, Moulton H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020; 3(9). Epub 2020/07/25. https://doi.org/10.7554/elife.64508 PMID: 32703818; PubMed Central PMCID: PMC7383062.
5. Mykytyn AZ, Breugem TI, Riebebosch S, Schipper D, van den Doel PB, Rottier RJ, et al. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. Elife. 2021; 10. Epub 2021/01/05. https://doi.org/10.7554/eLife.64508 PMID: 33393462; PubMed Central PMCID: PMC7806259.
6. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc Natl Acad Sci U S A. 2005; 102(35):12543–7. Epub 2005/08/24. https://doi.org/10.1073/pnas.0503203102 PMID: 16116101; PubMed Central PMCID: PMC1194915.
7. Tang JW, Tambyah PA, Hui DS. Emergence of a new SARS-CoV-2 variant in the UK. J Infect. 2021; 82(4):e27–e8. Epub 2021/01/01. https://doi.org/10.1016/j.jinf.2020.12.024 PMID: 33383088; PubMed Central PMCID: PMC7834693.

8. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med. 2021. Epub 2021/05/29. https://doi.org/10.1038/s41591-021-01397-4 PMID: 34045737.

9. van Dorp CH, Goldberg EE, Hengartner N, Ke R, Romero-Severson EO. Estimating the strength of selection for new SARS-CoV-2 variants. medRxiv. 2021. Epub 2021/04/07. https://doi.org/10.1101/2021.03.29.21254233 PMID: 33821289; PubMed Central PMCID: PMC8020992.

10. Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021; 595(7865):17–8. Epub 2021/06/24. https://doi.org/10.1038/d41586-021-01696-3 PMID: 34158664.

11. Mohammad M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz J Infect Dis. 2021; 25(4):101606. Epub 2021/08/25. https://doi.org/10.1016/j.bjid.2021.101606 PMID: 34428473; PubMed Central PMCID: PMC8367756.

12. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020; 27(5):1451–5. Epub 2020/03/25. https://doi.org/10.1038/s41418-020-0530-3 PMID: 32205856; PubMed Central PMCID: PMC7091918.

13. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020; 55:102763. Epub 2020/05/04. https://doi.org/10.1016/j.ebiom.2020.102763 PMID: 32361250; PubMed Central PMCID: PMC7165294.

14. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev. 2010; 62(4):726–59. Epub 2010/11/17. https://doi.org/10.1124/pr.110.002733 PMID: 21079042; PubMed Central PMCID: PMC2993259.

15. Eichelberger KR, Goldman WE. Manipulating neutrophil degranulation as a bacterial virulence strategy. PLoS Pathog. 2020; 16(12):e1009054. Epub 2020/12/11. https://doi.org/10.1371/journal.ppat.1009054 PMID: 33301542; PubMed Central PMCID: PMC7728292.

16. Akgun E, Tuzuner MB, Sahin B, Kilercik M, Kulah C, Cakiroglu HN, et al. Proteins associated with neutrophil degranulation are upregulated in nasopharyngeal swabs from SARS-CoV-2 patients. PLoS One. 2020; 15(10):e0240012. Epub 2020/10/21. https://doi.org/10.1371/journal.pone.0240012 PMID: 33079950; PubMed Central PMCID: PMC7575075 interests: MBT, BS, CK, HNC, and IU are employees of Acibadem Labmed Clinical Laboratory. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.

17. Mustafa Z, Zhanapiya A, Kalbacher T. Neutrophil Elastase and Proteinase 3 Cleavage Sites Are Adjacent to the Polybasic Sequence within the Proteolytic Sensitive Activation Loop of the SARS-CoV-2 Spike Protein. ACS Omega. 2021; 6(10):7181–5. Epub 2021/03/23. https://doi.org/10.1021/acsomega.1c00363 PMID: 33748632; PubMed Central PMCID: PMC7861537.

18. Oleksyszyn J, Powers JC. Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. Biochemistry. 1991; 30(2):485–93. Epub 1991/01/15. https://doi.org/10.1021/bi00216a026 PMID: 1988040.

19. Andreano E, Rappuoli R. SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. Nat Med. 2021; 27(5):759–61. Epub 2021/05/12. https://doi.org/10.1038/s41591-021-01347-0 PMID: 33972793.

20. Jaimes J, Millet J, Whittaker G. Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site. SSRN. 2020;3581359. Epub 2020/07/28. https://doi.org/10.2139/ssrn.3581359 PMID: 32714113; PubMed Central PMCID: PMC7366798.

21. Kasperkiewicz P, Poreba M, Snipas SJ, Parker H, Winterbourn CC, Salvesen GS, et al. Design of ultra-sensitive probes for human neutrophil elastase through hybrid combinatorial substrate library profiling. Proc Natl Acad Sci U S A. 2014; 111(7):2518–23. Epub 2014/02/20. https://doi.org/10.1073/pnas.1318548111 PMID: 24550277; PubMed Central PMCID: PMC3932852.

22. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Eichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020. Epub 2020/03/07. https://doi.org/10.1016/j.cell.2020.02.052 PMID: 32142651; PubMed Central PMCID: PMC7102627.

23. Papa G, Mallory DL, Albecka A, Welch LG, Cattin-Ortola J, Luptak J, et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion. PLoS Pathog. 2021; 17(1): e1009246. Epub 2021/01/26. https://doi.org/10.1371/journal.ppat.1009246 PMID: 33493182; PubMed Central PMCID: PMC7861537.
24. Goettig P. Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Int J Mol Sci. 2016; 17(12). Epub 2016/11/30. https://doi.org/10.3390/ijms17121969 PMID: 27898009; PubMed Central PMCID: PMC5187769.

25. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020; 26(4):450–2. Epub 2020/04/15. https://doi.org/10.1038/s41591-020-0820-9 PMID: 32284615.

26. Ramanathan M, Ferguson ID, Miao W, Khavari PA. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis. 2021; 21(8):1070. Epub 2021/05/23. https://doi.org/10.1016/S1473-3099(21)00262-0 PMID: 34022142; PubMed Central PMCID: PMC8133765.

27. Scudellari M. How the coronavirus infects cells—and why Delta is so dangerous. Nature. 2021; 595 (7869):640–4. Epub 2021/07/30. https://doi.org/10.1038/d41586-021-02039-y PMID: 34321669.